biotech
Fda Tells uniQure Early Trial Data Insufficient for Brain Disorder Therapy Filing
EU Regulator Backs Approval for Moderna's Combined Covid and Flu Vaccine
Eli Lilly's Weight-Loss Pill Shows Higher Side Effects Than Novo Rival in Diabetes Trial
Novo Nordisk Partners With Vivtex in up to $2.1 Billion Deal for Oral Obesity Drugs
Eqt Backs Out of Takeover Bid for UK's Oxford Biomedica
Date: February 25, 2026
Feb 25 (Reuters) - Private equity group EQT said on Wednesday it had decided not to proceed with a takeover offer for Oxford Biomedica, sending the British cell and gene therapy manufacturer's shares...
Novartis to Build Radioligand Therapy Site in Texas to Expand US Manufacturing
Date: February 25, 2026
Feb 25 (Reuters) - Novartis said on Wednesday it intends to build a radioligand therapy manufacturing site in Texas, expanding its U.S. footprint with what will be its first such facility in the state...
Gsk to Buy 35Pharma for $950 Million in CEO Miel's Second Major Deal
Date: February 25, 2026
Feb 25 (Reuters) - GSK on Wednesday agreed to pay $950 million in cash for Canadian biopharmaceutical company 35Pharma Inc, which is developing a medicine for pulmonary hypertension. The deal marks...
Barclays Slashes Sales Forecasts for Novo's CagriSema by More Than 80%
Date: February 24, 2026
By Maggie Fick LONDON, Feb 24 (Reuters) - Barclays analysts on Tuesday slashed their peak sales forecasts for Novo Nordisk's next-generation obesity drug CagriSema to just $2 billion from $12 billion...
Instant View: Novo's CagriSema Setback May Shift Investor Focus to M&A Strategy, Analysts Say
Date: February 23, 2026
Feb 23 (Reuters) - Novo Nordisk's next-generation weight-loss drug CagriSema was less effective than Eli Lilly's Zepbound in a head-to-head trial, a fresh blow to the Danish drugmaker's efforts to...
Novo Nordisk's CagriSema Trial Deals Blow in Obesity Drug Battle With Eli Lilly
Date: February 23, 2026
COPENHAGEN, Feb 23 (Reuters) - Novo Nordisk said on Monday its experimental obesity drug CagriSema did not meet the primary endpoint in a trial designed to show it was non-inferior to competitor Eli...